We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Rivaroxaban Safety Profile in the Prophylaxis of Venous Thromboembolism After Hip Fracture Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01509118
Recruitment Status : Unknown
Verified January 2012 by Dr.Thanainit Chotanaphuti, Phramongkutklao College of Medicine and Hospital.
Recruitment status was:  Recruiting
First Posted : January 12, 2012
Last Update Posted : January 12, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
Arterial and venous thromboembolism represents one of the most common preventable health problems. Patients undergoing surgery, especially hip fracture surgery are at high risk for deep vein thromboembolism (VTE) without thromboprophylaxis. In the absence of prophylaxis, the incidence of fatal pulmonary embolism (PE) after Hip Fracture Surgery (HFS) is reportedly 4%-12%. Provision of thromboprophylaxis to all patients who undergo HFS is recommended.

Condition or disease
Open Fracture of Hip

Detailed Description:
Rivaroxaban is the first agent of a new class of drugs acting as direct factor Xa inhibitors with oral bioavailability. Highly selective inhibition of factor Xa by rivaroxaban is expected to inhibit the amplified burst of thrombin generation and may result in more effective inhibition of thrombus formation with a favorable safety profile. In Thailand rivaroxaban is indicated for the prevention of VTE in patients undergoing major orthopedic surgery of the lower limbs including surgery for hip fractures. There are limited number of observational studies of rivaroxaban in thromboembolism after hip fracture surgery as the approved indication in most countries are for thromboprophylaxis in hip and knee arthroplasty. The broader indications and the high number of hip fracture surgeries in Thailand allow us to explore a pattern of safety profile particularly bleeding complications and risk factors in patients receiving rivaroxaban thromboprophylaxis after hip fracture surgery.

Study Design

Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Rivaroxaban Safety Profile in the Prophylaxis of Venous Thromboembolism After Hip Fracture Surgery
Study Start Date : July 2011
Estimated Primary Completion Date : June 2013
Estimated Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Rivaroxaban
U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Rivaroxaban safety profile will be observed in 500 patients

Inclusion Criteria:

  • At least 50 years old in men or post-menopause in women
  • Patients, who are undergoing standard surgery for fracture of the upper third of the femur, including femoral head, neck, trochanteric and sub-trochanteric fracture and the surgery is planned within 7 days after admission
  • Patients, who are eligible for thromboprophylaxis. Such patients will be enrolled only after physician's decision to prescribe rivaroxaban for thromboprophylaxis has been made. The decision is totally based on standard of medical practice.
  • Patients, who agree to participate, return to follow-up visits, and who have signed informed consent to participate in the study.

Exclusion Criteria:

  • Trauma affecting more than 1 organ system
  • Pathological fracture secondary to malignant disease
  • Clinically significant bleeding excluding drainage
  • Documented congenital or acquired bleeding disorder
  • Patients, who have contraindications for thromboprophylaxis or contraindications to take rivaroxaban according to FDA-approved product label
  • Patient on oral anticoagulation therapy in the past 7 days
  • Pregnancy or breastfeeding
  • Patients who are simultaneously participating in a different study
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01509118

Department of Orthopaedics, Chulalongkorn Hospital Recruiting
Pathumwan, Bangkok, Thailand, 10330
Contact: Aree Tanavalee, MD.    662-256-4212    areetana@hotmail.com   
Principal Investigator: Aree Tanavalee, M.D.         
Department of Orthopedic Surgery, Police General Hospital Recruiting
Pathumwan, Bangkok, Thailand, 10400
Contact: Thana Turajane, MD.    662 3193025    thanaturajane@yahoo.com   
Principal Investigator: Thana Turajane, MD.         
Department of Orthopaedic surgery Pharmongkutklao Hospital Recruiting
Rajathevee, Bangkok, Thailand, 10400
Contact: Thanainit Chotanaphut, M.D.    662 3547600 ext 93504    me-pmk@hotmail.com   
Principal Investigator: Thanainit Chotanaphut, M.D.         
Department of Orthopaedic Surgery,Chiang Mai University Recruiting
Muang, Chiang Mai, Thailand, 50200
Contact: Prasit Wongtriratanachai, MD.    66-5394-5544    prasitjo@gmail.com   
Principal Investigator: Prasit Wongtriratanachai, MD.         
Department of Orthopaedics, Thammasat University Recruiting
Klong Luang, Pathumthani, Thailand, 12121
Contact: Boonchana Pongcharoen, MD.    662 9269775    boonbigbear@hotmail.com   
Principal Investigator: Boonchana Pongcharoen, MD.         
Orthopedic/Board of Orthopedic Surgery, Saint Louis Hospital Recruiting
Bangkok, Thailand, 10120
Contact: Thanin Santhanavanich, MD.    662 210 9999    thanin@saintlouis.or.th   
Principal Investigator: Thanin Santhanavanich, MD.         
Department of Orthopedic Surgery, Bhumibol Adulyadej Hospital Not yet recruiting
Bangkok, Thailand, 10220
Contact: Thana Narinsorasak, MD.    662 5347000 ext 27365      
Principal Investigator: Thana Narinsorasak, MD.         
Sponsors and Collaborators
Phramongkutklao College of Medicine and Hospital
Chulalongkorn University
Chiang Mai University
Thammasat University
Police General Hospital
Saint Louis Hospital,bangkok,Thailand
Bhumibol Adulyadej Hospital
Principal Investigator: Thanainit Chotanaphut, M.D. Department of Orthopaedic Surgery Pharmongkutklao Hospital
More Information

Responsible Party: Dr.Thanainit Chotanaphuti, Colonel, Phramongkutklao College of Medicine and Hospital
ClinicalTrials.gov Identifier: NCT01509118     History of Changes
Other Study ID Numbers: 15635
First Posted: January 12, 2012    Key Record Dates
Last Update Posted: January 12, 2012
Last Verified: January 2012

Additional relevant MeSH terms:
Fractures, Bone
Venous Thromboembolism
Hip Fractures
Fractures, Open
Wounds and Injuries
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Femoral Fractures
Hip Injuries
Leg Injuries
Factor Xa Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action